WO2008130137A1 - Anionic lipid nanosphere and preparation method of the same - Google Patents
Anionic lipid nanosphere and preparation method of the same Download PDFInfo
- Publication number
- WO2008130137A1 WO2008130137A1 PCT/KR2008/002174 KR2008002174W WO2008130137A1 WO 2008130137 A1 WO2008130137 A1 WO 2008130137A1 KR 2008002174 W KR2008002174 W KR 2008002174W WO 2008130137 A1 WO2008130137 A1 WO 2008130137A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- drug
- peg
- nanosphere
- preparation
- Prior art date
Links
- 239000002077 nanosphere Substances 0.000 title claims abstract description 119
- -1 Anionic lipid Chemical class 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 150000002632 lipids Chemical class 0.000 claims abstract description 127
- 239000003814 drug Substances 0.000 claims abstract description 83
- 229940079593 drug Drugs 0.000 claims abstract description 82
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 70
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000002245 particle Substances 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 21
- 239000012736 aqueous medium Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 47
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 44
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 37
- 229960003942 amphotericin b Drugs 0.000 claims description 37
- 239000003960 organic solvent Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 15
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 229930182558 Sterol Natural products 0.000 claims description 10
- 150000003432 sterols Chemical class 0.000 claims description 10
- 235000003702 sterols Nutrition 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 7
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 claims description 4
- BIABMEZBCHDPBV-ZPGRZCPFSA-N 1,2-dipalmitoyl-phosphatidyl-glycerole Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@](O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-ZPGRZCPFSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- ZWZWYGMENQVNFU-AKGZTFGVSA-N glycerol 1-phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-AKGZTFGVSA-N 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- LLCSXHMJULHSJN-UHFFFAOYSA-N glycerophosphoglycerol Chemical compound OCC(O)COP(O)(=O)OCC(O)CO LLCSXHMJULHSJN-UHFFFAOYSA-N 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 238000000527 sonication Methods 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001427 mPEG Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical group COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims 1
- JZNWSCPGTDBMEW-YFKPBYRVSA-N sn-glycero-3-phosphoethanolamine Chemical compound NCCO[P@@](O)(=O)OC[C@@H](O)CO JZNWSCPGTDBMEW-YFKPBYRVSA-N 0.000 claims 1
- 230000004087 circulation Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 16
- 238000005538 encapsulation Methods 0.000 abstract description 12
- 231100000419 toxicity Toxicity 0.000 abstract description 12
- 230000001988 toxicity Effects 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 50
- 229940067631 phospholipid Drugs 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
- 150000001450 anions Chemical group 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229940098178 ambisome Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to an anionic lipid nanosphere having negative surface charge and a method of its preparation, more particularly to a lipid nanosphere prepared by introducing polyethylene glycol (PEG) containing polymers on the surface of particles formed of anionic phospholipids to provide negative charge on the surface, thereby increasing encapsulation efficiency of a poorly water soluble drug in an aqueous medium, reducing toxicity of highly toxic drug against normal cells by encapsulating therewith, and increasing duration of circulation in the body, and a method of its preparation.
- PEG polyethylene glycol
- Amphotericin B is a polyene antifungal drug effective in treating almost all fungal infections, particularly systemic fungal infections. Therefore, amphotericin B is used for the treatment of severe life-threatening infections in patients with cancer, bone-marrow transplantation, neutropenia, immune compromise or immune deficiency. Amphotericin B associates with ergosterol, a membrane chemical of fungi, forms a pore that leads to relocation of ion passage, interferes with osmosis control of fungal cells, thereby providing antifungal and antibiotic therapeutic effect.
- amphotericin B when administered intraveneously, amphotericin B also associates with cholesterol of normal cells, thereby becoming toxic to normal cells and tissues, and accompanied by side effects such as shaking chills, fever, tissue necrosis, renal toxicity, and the like.
- a special care is essential in its use and medication because amphotericin B is not easily discharged by hemodialysis. Particularly, a good care is needed when used for children, the elderly or patients with weak immunity because of its strong renal toxicity.
- Amphotericin B is insoluble in water at pH 6 to 7, and hardly soluble at pH 2 or pH
- amphotericin B by preparing it into a salt formulation.
- an amphotericin B composition is prepared from particles of amphotericin B and cholesterol sulfate having particle sizes between about 100 and 400 nm, thereby improving solubility in an aqueous medium.
- US Patent No. 5,059,591 teaches a method of reducing the toxicity of amphotericin B by using a complex of amphotericin B and cholesterol-polyethylene glycol (PEG).
- PEG cholesterol-polyethylene glycol
- the inventors of the present invention have made various efforts to solve the aforementioned problems associated with the prior art. As a result, they have succeeded in inventing an anionic lipid nanosphere for encapsulating a poorly water soluble drug such as amphotericin B and a method of its preparation. By modifying the surface of the lipid nanosphere having superior bioaffinity with an anionic material and encapsulating the highly toxic drug therein, it is possible to reduce toxicity to normal cells and provide sustained release of the drug.
- an object of the present invention is to provide an anionic lipid nanosphere for encapsulating a poorly water soluble drug in which the surface of a particle formed of anionic phospholipids is modified with a polyethylene glycol (PEG) containing polymer.
- PEG polyethylene glycol
- Another object of the present invention to provide a preparation method of the anionic lipid nanosphere modified with a PEG containing polymer.
- the present invention relates to a preparation method of an anionic lipid nanosphere in which a PEG containing polymer is introduced on the surface of a lipid nanosphere formed of anionic phospholipids either by mixing a PEG containing polymer with a phospholipid (A) or by forming an ion complex of phospholipid and PEG having a terminal amine group (B).
- step (A-3) mixing the lipid- PEG mixture solution of step (A-I) with the drug solution of step (A-2) with a volume ratio of 1 : 1 to 1 :9 to obtain a lipid-PEG-drug mixture solution
- the present invention provides a preparation methodof an anionic lipid nanosphere for encapsulating a poorly water soluble drug, comprising the steps of:
- step (B-4) dispersing the mixture solution of step (B-3) in an aqueous medium with a volume ratio of 2: 1 to 1 : 10 to form lipid nanospheres
- step (B-5) distilling the lipid nanosphere solution of step (B-4) at 20 to 5O 0 C under reduced pressure, removing the organic solvent, and filtering to obtain anionic lipid nanospheres with uniform size in which the drug is encapsulated and
- the present invention relates to an anionic lipid nanosphere for encapsulating a poorly water soluble drug in which a PEG containing polymer is introduced on the surface of particles formed of anionic phospholipidsto increase encapsulation efficiency of a poorly water soluble drug in an aqueous medium, and the highly toxic drugis encapsulated in a lipid nanosphere with superior bioaffinity to reduce toxicity to normal cells and increase circulation time in the blood, and a method of its preparation.
- the present invention is characterized in that an anionic phospholipid is used to prepare a lipid nanosphere for encapsulating a poorly water soluble drug.
- the anionic phospholipid is phosphatidic acid having a hydrophobic Ci 4 -Ci 8 alkyl chain.
- dimyristyl glycerophosphate DMPA
- dipalmitoyl glycerophosphate DPPA
- dimyristyl glycerophosphate DMPG
- disteroyl glycerophosphate DSPA
- disteroyl glycerophosphoglycerol DSPG
- dipalmitoyl glycerophosphoglycerol DPPG
- dimyristyl glycerophosphoserine DMPS
- dipalmitoyl glycerophosphoserine DPPS
- disteroyl glycerophosphoserine DSPS
- the anionic phospholipid When the anionic phospholipid has less than 14 carbon atoms, stability of the lipid nanosphere in vivo decreases as the phase transition temperature is below the body temperature. In contrast, when the anionic phospholipid has more than 18 carbon atoms, encapsulation efficiency of the poorly water soluble drug decreases because of weak binding to the drug, and particle size of the lipid nanosphere increases.
- the anionic lipid is contained in an amount of 5 to 20 weight % based on the entire lipid composition constituting the lipid nanosphere.
- the lipid for forming the lipid nanosphere of the present invention it is preferable to use either hydrogenated phosphatidylcholine or phosphatidylcholine.
- Soybean phosphatidylcholine, egg yolk phosphatidylcholine or bovine phospholipid may be used. More preferably, one having a hydrophobic Ci 6 -Ci 8 alkyl chain is used.
- dipalmitoyl phosphatidylcholine or distearoyl phosphatidylcholine, etc. may be used.
- a strong binding to amphoteric amphotericin B is attained even when the number of carbons is less than 16, but stability of the lipid nanosphere in vivo decreases as the phase transition temperature is below the body temperature.
- the number of carbons is larger than 18, encapsulation efficiency of the poorly water soluble drug decreases because of its weak binding to the drug, and particle size of the lipid nanosphere increases.
- the phosphatidylcholine is contained in an amount of 40 to 70 weight % based on the entire lipid composition constituting the lipid nanosphere.
- sterol is used as a lipid for forming the lipid nanosphere.
- preferred sterol include cholesterol, cholesterol hexasuccinate, 3 ⁇ -[/V-(/V,./V '- dimethylaminoethane)carbamoyl]cholesterol, ergosterol, stigmasterol, lanosterol, etc.
- the sterol is contained in an amount of 10 to 40 weight % based on the entire lipid composition constituting the lipid nanosphere.
- a PEG containing polymer is introduced to the lipid nanosphere in order to modify the surface of the lipid nanosphere in which the drug is encapsulated.
- a PEG containing polymer selected from disteroyl glycerophosphoethanolamine methyloxy ethylene glycol (DSPE- mPEG), poly- oxyethylene sorbitan monopalmitate (Tween), polyethylene polypropylene glycol (poloxamer) and a mixture thereof may be used.
- the polymer is contained in an amount of 10 to 30 parts by weight based on 100 parts by weight of the total lipid.
- the surface of the lipid nanosphere may not be sufficiently modified with PEG.
- the content of the PEG containing polymer exceeds 30 parts by weight, the surface of the lipid nanosphere is not further modified because the surface area is limited.
- PEG an ion complex is formed by the anionic groups on the surface of the lipid nanosphere and the terminal amine groups of the PEG.
- PEG is introduced on the surface of the lipid nanosphere by the lipophilic binding between the liposoluble moieties of the PEG containing lipid, or other lipid, phospholipid and cholesterol.
- the "drug” means a poorly water soluble drug which is not easily encapsulable in conventional drug delivery systems.
- Amphotericin B is a typical example, but the present invention is not limited thereto.
- the lipid nanosphere of the present invention in which amphotericin B is encapsulated and the surface of which is modified with anions, has an average particle size of 50 to 300 nm, preferably 100 to 150 nm.
- the average particle size of the lipid nanosphere is larger than 300 nm, the lipid nanosphere may be uptaken by the reticuloendothelial system of such organs as liver or spleen during circulation in blood.
- the average particle size of the lipid nanosphere is smaller than 50 nm, the amount of the drug reaching the target site (drug payload) may not be sufficient.
- the method (A) of mixing a PEG containing lipid with a lipid is as follows.
- step (A-I) phosphatidylcholine, anionic phospholipid and sterolare mixed with a weight ratio of 40-70 : 5-20 : 10-40 to obtain a lipid.
- a lipid nanosphere is not formed easily when the content of phosphatidylcholine is less than the aforementioned range, and stability of the lipid nanosphere decreases when the content exceeds the aforementioned range.
- the size of the lipid nanosphere may increase and lipid nanospheres may coagulate with each other when the content of anionic phospholipid is less than the aforementioned range, and particle size may increase because of coagulation of lipid nanospheres with PEG when the content exceeds the aforementioned range.
- encapsulation efficiency of the drug may decrease when the content of cholesterol is less than the aforementioned range, and stability of the lipid nanosphere may decrease when the content exceeds the aforementioned range.
- Encapsulation efficiency of the drug increases as the weight ratio of sterol increases. But, aforementioned range is preferred because particle size increases when the content of sterol exceeds the aforementioned range.
- lipid-PEG mixture solution One hundred parts by weight of thus prepared lipid is mixed with 10 to 30 parts by weight of a PEG containing polymer and dissolved in an organic solvent to obtain a lipid-PEG mixture solution.
- Coating of PEG may not be performed easily when the content of the PEG containing polymer is less than 10 parts by weight, and particle size becomes too large when the content the content exceeds 30 parts by weight. Hence, the aforementioned range is preferred to be kept.
- the lipid for forming the lipid nanosphere is dissolved in an organic solvent capable of dissolving lipids, such as chloroform, methanol, toluene, and the like.
- a poorly water soluble drug is dissolved in a Ci-C 6 linear or branched alcoholto obtain a drug solution.
- the Ci-C 6 linear or branched alco- holin include methanol, ethanol, propanol, butanol, isobutanol, isopropanol, and the like.
- the poorly water soluble drug is dissolved in the alcohol to a concentration of 0.1 to 1 mg/mL.
- the poorly water soluble drug preferably amphotericin B
- the concentration of the encapsulated drug decreases.
- the concentration exceeds 1 mg/mL the drug may not be completely dissolved in the alcohol.
- an organic solvent other than alcohol e. g., dimethyl sulfoxide (DMSO), dimethylformamide (DMF), etc.
- step (A-3) the lipid-PEG mixture solution of step (A-I) and the drug solution of step (A-2) are mixed with a volume ratio of 1:1 to 1:9 to obtain a lipid-PEG-drug mixture solution.
- concentration of the drug decreases.
- formulation may be difficult because the quantity of the phospholipid is too small.
- step (A-4) the lipid-PEG-drug mixture solution of step (A-3) is dispersed in an aqueous medium with a volume ratio of 2:1 to 1:10, more preferably 1:1 to 1:3, to obtain lipid nanospheres.
- aqueous medium distilled water, phosphate buffer, saline solution, sugar solution, e.g., sucrose solution, maltose solution, mannitol solution, and the like, or isotonic solution may be used.
- the volume of the aqueous medium is less than the aforementionedrange, the dispersed lipid nanosphere particles may coagulate, thereby resulting in increase in particle size of the final lipid nanospheres.
- step (A-5) the lipid nanosphere solution of step (A-4) is distilled at 20 to 5O 0 C under reduced pressure to remove the organic solvent, and filtered to obtain lipid nanospheres with uniform particle size and having PEG groups, in which the drug is encapsulated.
- the temperature during the distillation under reduced pressure is below 2O 0 C, it takes longer to remove the organic solvent and it is difficult to completely remove the organic solvent.
- the temperature exceeds 5O 0 C the lipid nanospheres may be damaged or the drug may be denatured. Hence, it is preferable to maintain the aforementioned temperature range.
- the purified lipid nanosphere solution is subjected to an injection molding machine to obtain a solution of lipid nanospheres having a uniform particle size distributed between 0.1 and 0.5 ⁇ m.
- the filter membrane used in the injection molding machine has a pore size of 0.1 to 0.5 ⁇ m, identical to the particle size of the lipid nanospheres.
- the particle size of the lipid nanosphere becomes larger than 0.5 ⁇ m, thus resulting in blockage at capillaries or uptake by reticuloendothelial cells during intraveneous injection, and consequent abrupt decrease of circulation time in the blood.
- the pore size is smaller than 0.1 ⁇ m, most of the particles pass through semipermeable membranes, thereby resulting in abrupt decrease of availability.
- dialysis, gel permeation chromatography, filtration at high pressure, and the like may be performed to remove free PEGs remaining without being used to modify the lipid nanospheres. More preferably, gel permeation chromatography is performed to remove them along with phospholipids, drug, etc., remaining without being included in the lipid nanosphere.
- the method (B) of forming an ion complex comprising lipid and PEG having terminal amine groups is as follows.
- step (B-I) phosphatidylcholine, anionic phospholipid and sterol are mixed with a weight ratio of 40-70 : 5-20 : 10-40 to obtain a lipid mixture solution, as in step (A-I).
- step (B -2) a poorly water soluble drug is dissolved in a Ci-C 6 linear or branched alcohol to obtain a drug solution, as in step (A-2).
- step (B-3) the lipid mixture solution of step (B-I) and the drug solution of step
- step (B-4) the mixture solution of step (B-3) is dispersed in an aqueous medium with a volume ratio of 2: 1 to 1:10, more preferably 1 : 1 to 1 :3, to obtain lipid nanospheres, as in step (A-4).
- step (B-5) the lipid nanosphere solution of step (B-4) is distilled at 20 to 5O 0 C under reduced pressure to remove the organic solvent, and filtered to obtain lipid nanospheres with uniform particle size, in which the drug is encapsulated, as in step (A-5).
- step (B-6) the lipid of step (B-I) is mixed with a PEG having terminal amine groups with a weight ratio of 100:10 to 100:30 and, after adjusting pH to 1 to 4, heating is performed at 40 to 65 0 C for 10 to 30 minutes, so that the lipid and the PEG form an ion complex on the surface of the anionic lipid nanospheres, to obtain lipid nanospheres on which PEG is coated. That is, the PEG is coated on the surface of the lipid nanospheres as an ion complex is formed by the bonding of the anionic groups present on the surface of the lipid nanospheres with the terminal amine groups of the PEG.
- An acidic pH condition is selected to facilitate the formation of an ion complex.
- reaction temperature When the reaction temperature is below 5O 0 C, the reaction requires a longer time. In contrast, when reaction temperature is above 65 0 C, stability of the lipid nanospheres may be deteriorated.
- PEG having terminal amine groups include aminopolyethylene glycol, diaminopolyethylene oxide, amino(polyethylene glycol) methyl ether, and other polyethylene glycol or polyethylene oxide having terminal amine groups.
- dialysis, gel permeation chromatography, filtration at high pressure, and the like may be performed to remove free PEGs remaining without being used to modify the lipid nanospheres. More preferably, gel permeation chromatography is performed to remove them along with phospholipids, drug, etc., remaining without being included in the lipid nanosphere.
- anionic lipid nanospheres have improved encapsulation efficiency of a poorly water soluble drug in an aqueous medium and increase circulation time in blood because the surface of the lipid nanospheres is modified by introducing the PEG containing polymer thereon. Accordingly, they are expected to be useful in solubilizing various poorly water soluble drugs, including amphotericin B.
- DLPC dimyristoyl phosphatidylcholine
- DPPC dipalmitoyl phosphatidylcholine
- DSPC distearoyl phosphatidylcholine
- Amphotericin B (AmB) was dissolved in methanol to a concentration of 0.5 mg/mL.
- the AmB-lipid mixture solution in the amount of 10 mL, was dispersed in 20 mL of distilled water by tip sonication at a rate of 2 mL/min using a syringe to form lipid nanospheres.
- the organic solventand distilled water in the amount of 10 mL, respectively, were removed at 35 0 C by distillation under reduced pressure until the volume of the solution decreased to 10 mL.
- Particle size distribution of the lipid nanospheres was made uniform by passing them through a 0.2 ⁇ m semipermeable membrane using an extruder.
- Preparation Example 2 Preparation of lipid nanospheres comprising anionic phos- pholipids
- Anionic lipid nanospheres were prepared in the same manner as in Preparation Example 1, except for adding anionic phospholipids dipalmitoyl glycerophosphate (DPPA) or disteroyl glycerophosphoglycerol (DSPG) in order to improve the encapsulation of Sample 3, which has a particle size smaller than 150 nm and T g of 41 0 C, to 90% or better.
- DPPA dipalmitoyl glycerophosphate
- DSPG disteroyl glycerophosphoglycerol
- Preparation Example 3 Preparation of PEG coated lipid nanospheres (A) [74] Anionic lipid nanospheres were prepared in the same manner as in Preparation Example 2, except for adding 0 to 80 parts by weight of a DSPE-mPEG2000 solution to 100 parts by weight of the lipid mixture solution (Sample 8). Change of particle size depending on the content of DSPE-mPEG2000 is given in the following Table 4.
- the supernatant was diluted with a solution of 0.5 ⁇ g/mL of l-amino-4-nitronaphthalene in methanol.
- Ab- sorbance was measured using a UV spectrometer at a wavelength of 408 nm.
- the PEG coated lipid nanospheres according to the present invention [Sample 14 (Preparation Example 3) and Sample 18 (Preparation Example 4)] exhibited much longer circulation time in blood than Fungizone, and longer circulation time in blood than AmBisomeuntil 3 hours after injection. This demonstrates that the injections including the PEG coated anionic lipid nanospheres according to the present invention (Sample 14 and Sample 18) provide improved circulation time in blood over existing amphotericin B formulations.
- Test Example 2 Toxicity test
- MTT test was carried out using human kidney 293 cells. 293 cells were cultured on a
- the present invention relates to an anionic lipid nanosphere having negative surface charge prepared by introducing PEG containing polymers on the surface of particles formed of anionic phospholipids to provide negative charge on the surface, thereby increasing encapsulation efficiency of a poorly water soluble drug in an aqueous medium, reducing toxicity of highly toxic drug against normal cells by encapsulating, and increasing the duration of systemic circulation, and a method of its preparation.
- the present invention will be very useful for solubilization poorly water soluble drugs such as amphotericin B in an aqueous medium for injection, reduction toxicity thereof and increaseof circulation time in blood.
Abstract
Disclosed is an anionic lipid nanosphere having negative surface charge and a method of its preparation, more particularly to a lipid nanosphere prepared by introducing polyethylene glycol (PEG) containing polymers on the surface of particles formed of anionic phospholipids to provide negative charge on the surface, thereby increasing encapsulation efficiency of a poorly water soluble drug in an aqueous medium, reducing toxicity of highly toxic drug against normal cells by encapsulating therewith, and increasing duration of circulation in the body, and a method of its preparation.
Description
Description
ANIOIC LIPID NANOSPHERE AND PREPARATION METHOD
OF THE SAME
Technical Field
[1] The present invention relates to an anionic lipid nanosphere having negative surface charge and a method of its preparation, more particularly to a lipid nanosphere prepared by introducing polyethylene glycol (PEG) containing polymers on the surface of particles formed of anionic phospholipids to provide negative charge on the surface, thereby increasing encapsulation efficiency of a poorly water soluble drug in an aqueous medium, reducing toxicity of highly toxic drug against normal cells by encapsulating therewith, and increasing duration of circulation in the body, and a method of its preparation. Background Art
[2] Amphotericin B is a polyene antifungal drug effective in treating almost all fungal infections, particularly systemic fungal infections. Therefore, amphotericin B is used for the treatment of severe life-threatening infections in patients with cancer, bone-marrow transplantation, neutropenia, immune compromise or immune deficiency. Amphotericin B associates with ergosterol, a membrane chemical of fungi, forms a pore that leads to relocation of ion passage, interferes with osmosis control of fungal cells, thereby providing antifungal and antibiotic therapeutic effect.
[3] However, when administered intraveneously, amphotericin B also associates with cholesterol of normal cells, thereby becoming toxic to normal cells and tissues, and accompanied by side effects such as shaking chills, fever, tissue necrosis, renal toxicity, and the like. A special care is essential in its use and medication because amphotericin B is not easily discharged by hemodialysis. Particularly, a good care is needed when used for children, the elderly or patients with weak immunity because of its strong renal toxicity.
[4] Amphotericin B is insoluble in water at pH 6 to 7, and hardly soluble at pH 2 or pH
11, with a very low solubility of 0.1 mg/mL. For intraveneous injection, it is made soluble by preparing into salt, micelle, emulsion, nanosphere or liposome.
[5] US Patent No. 4,822,777 discloses a method for improving solubility of amphotericin
B by preparing it into a salt formulation. Specifically, an amphotericin B composition is prepared from particles of amphotericin B and cholesterol sulfate having particle sizes between about 100 and 400 nm, thereby improving solubility in an aqueous medium. Although solubility of amphotericin B was improved by the method in the above patent, circulation time in the blood was still relatively short, administration
dose is limited, and toxicity to normal cells could not be avoided.
[6] US Patent No. 5,059,591 teaches a method of reducing the toxicity of amphotericin B by using a complex of amphotericin B and cholesterol-polyethylene glycol (PEG). By using the complex of amphotericin B and cholesterol-PEG, the time for its circulation in the blood was increased. However, its toxicity is more serious as compared to that of formulated amphotericin B.
[7] US Patent No. 4,981,690 discloses a method of preparing amphotericin B encapsulated within a liposome. According to the patent, phospholipid and cholesterol are used to prepare a pharmaceutical composition in multilamellar liposomal form. However, its circulation time in the blood may be relatively short because a substance that assists consistent circulation is not contained.
[8] US Patent No. 5,965,156 discloses a method of encapsulating amphotericin B into liposome. According to the patent, phosphatidylglycerol is acidified in an acidic organic solvent and amphotericin B is added to the acidified phosphatidylglycerol and a complex is formed between the phosphatidylglycerol and amphotericin B, thereby improving encapsulation efficiency and reducing toxicity. However, use of an acidic solution for ionic bonding of phosphatidylglycerol with amphotericin B causes a problem of increasing the loss of amphotericin due to the increased decomposition. Further, stability of the resulting preparation is deteriorated due to the decomposition by the acid catalyst, which results in burst release of amphotericin B.
[9] Accordingly, there is a need for the development of a novel drug delivery system capable of improving solubility of amphotericin B in an aqueous medium, reducing toxicity of the drug, increasing circulation time in the blood, and being applicable to commercial- scale production. Disclosure of Invention
[10] The inventors of the present invention have made various efforts to solve the aforementioned problems associated with the prior art. As a result, they have succeeded in inventing an anionic lipid nanosphere for encapsulating a poorly water soluble drug such as amphotericin B and a method of its preparation. By modifying the surface of the lipid nanosphere having superior bioaffinity with an anionic material and encapsulating the highly toxic drug therein, it is possible to reduce toxicity to normal cells and provide sustained release of the drug.
[11] Accordingly, an object of the present invention is to provide an anionic lipid nanosphere for encapsulating a poorly water soluble drug in which the surface of a particle formed of anionic phospholipids is modified with a polyethylene glycol (PEG) containing polymer.
[12] Another object of the present inventionto provide a preparation method of the anionic
lipid nanosphere modified with a PEG containing polymer. Brief Description of the Drawings
[13] FIG. 1 is a graph showing the pharmacokinetic test result of Test Example 1.
[14] FIG. 2 is a graph showing the toxicity test result of Test Example 2.
Best Mode for Carrying Out the Invention
[15] In one aspect, the present invention relates to an anionic lipid nanosphere for encapsulating a poorly water soluble drug in which a polyethylene glycol (PEG) containing polymer is coated on the surface of particles formed of anionic phospholipids.
[16] In another aspect, the present invention relates to a preparation method of an anionic lipid nanosphere in which a PEG containing polymer is introduced on the surface of a lipid nanosphere formed of anionic phospholipids either by mixing a PEG containing polymer with a phospholipid (A) or by forming an ion complex of phospholipid and PEG having a terminal amine group (B).
[17] In a preferred embodiment, the present invention relates to a method of preparing an anionic lipid nanosphere for encapsulating a poorly water soluble drug, comprising the steps of:
[18] (A-I) mixing 100 parts by weight of a lipid, which is prepared by mixing phosphatidylcholine, anionic phospholipid and sterol with a weight ratio of 40-70 : 5-20 : 10-40, with 10 to 30 parts by weight of a PEG containing polymer, and dissolving in an organic solvent to obtain a lipid- PEG mixture solution
[19] (A-2) dissolving a poorly water soluble drug in a Ci-C6 linear or branched alcohol to obtain a drug solution
[20] (A-3) mixing the lipid- PEG mixture solution of step (A-I) with the drug solution of step (A-2) with a volume ratio of 1 : 1 to 1 :9 to obtain a lipid-PEG-drug mixture solution
[21] (A-4) dispersing the mixture solution of step (A-3) in an aqueous medium with a volume ratio of 2:1 to 1:10 to form lipid nanospheres and
[22] (A-5) distilling the lipid nanosphere solution of step (A-4) at 20 to 5O0C under reduced pressure, removing the organic solvent, and filtering to obtain anionic lipid nanospheres with uniform size in which the drug is encapsulated.
[23] In another preferred embodiment, the present invention provides a preparation methodof an anionic lipid nanosphere for encapsulating a poorly water soluble drug, comprising the steps of:
[24] (B-I) dissolving a lipid prepared by mixing phosphatidylcholine, anionic phospholipid and sterol with a weight ratio of 40-70 : 5-20 : 10-40 in an organic solvent to obtain a lipid mixture solution
[25] (B-2) dissolving a poorly water soluble drug in a Ci-C6 linear or branched alcohol to
obtain a drug solution
[26] (B-3) mixing the lipid mixture solution of step (B-I) with the drug solution of step
(B-2) with a volume ratio of 1:1 to 1:9 to obtain a lipid-drug mixture solution
[27] (B-4) dispersing the mixture solution of step (B-3) in an aqueous medium with a volume ratio of 2: 1 to 1 : 10 to form lipid nanospheres
[28] (B-5) distilling the lipid nanosphere solution of step (B-4) at 20 to 5O0C under reduced pressure, removing the organic solvent, and filtering to obtain anionic lipid nanospheres with uniform size in which the drug is encapsulated and
[29] (B -6) mixing with a PEG having terminal amine groups with a weight ratio of the lipid of step (B-I) to the PEG having terminal amine groups being 100:10 to 100:30 to form lipid-PEG ion complexes.
[30] Hereunder is given a more detailed description of the present invention.
[31] The present invention relates to an anionic lipid nanosphere for encapsulating a poorly water soluble drug in which a PEG containing polymer is introduced on the surface of particles formed of anionic phospholipidsto increase encapsulation efficiency of a poorly water soluble drug in an aqueous medium, and the highly toxic drugis encapsulated in a lipid nanosphere with superior bioaffinity to reduce toxicity to normal cells and increase circulation time in the blood, and a method of its preparation.
[32] Particularly, the present invention is characterized in that an anionic phospholipid is used to prepare a lipid nanosphere for encapsulating a poorly water soluble drug. Preferably, the anionic phospholipid is phosphatidic acid having a hydrophobic Ci4-Ci8 alkyl chain. More preferably, it is selected from dimyristyl glycerophosphate (DMPA), dipalmitoyl glycerophosphate (DPPA), dimyristyl glycerophosphate (DMPG), disteroyl glycerophosphate (DSPA), disteroyl glycerophosphoglycerol (DSPG), dipalmitoyl glycerophosphoglycerol (DPPG), dimyristyl glycerophosphoserine (DMPS), dipalmitoyl glycerophosphoserine (DPPS), disteroyl glycerophosphoserine (DSPS) and a mixture thereof. When the anionic phospholipid has less than 14 carbon atoms, stability of the lipid nanosphere in vivo decreases as the phase transition temperature is below the body temperature. In contrast, when the anionic phospholipid has more than 18 carbon atoms, encapsulation efficiency of the poorly water soluble drug decreases because of weak binding to the drug, and particle size of the lipid nanosphere increases. Preferably, the anionic lipid is contained in an amount of 5 to 20 weight % based on the entire lipid composition constituting the lipid nanosphere.
[33] As the lipid for forming the lipid nanosphere of the present invention, it is preferable to use either hydrogenated phosphatidylcholine or phosphatidylcholine. Soybean phosphatidylcholine, egg yolk phosphatidylcholine or bovine phospholipid may be used. More preferably, one having a hydrophobic Ci6-Ci8 alkyl chain is used. For example, dipalmitoyl phosphatidylcholine or distearoyl phosphatidylcholine, etc. may be used. A
strong binding to amphoteric amphotericin B is attained even when the number of carbons is less than 16, but stability of the lipid nanosphere in vivo decreases as the phase transition temperature is below the body temperature. When the number of carbons is larger than 18, encapsulation efficiency of the poorly water soluble drug decreases because of its weak binding to the drug, and particle size of the lipid nanosphere increases. Preferably, the phosphatidylcholine is contained in an amount of 40 to 70 weight % based on the entire lipid composition constituting the lipid nanosphere.
[34] Further, sterol is used as a lipid for forming the lipid nanosphere. Examples of preferred sterol include cholesterol, cholesterol hexasuccinate, 3β-[/V-(/V,./V '- dimethylaminoethane)carbamoyl]cholesterol, ergosterol, stigmasterol, lanosterol, etc. Preferably, the sterol is contained in an amount of 10 to 40 weight % based on the entire lipid composition constituting the lipid nanosphere.
[35] In accordance with the present invention, a PEG containing polymer is introduced to the lipid nanosphere in order to modify the surface of the lipid nanosphere in which the drug is encapsulated. To this end, a PEG containing polymer selected from disteroyl glycerophosphoethanolamine methyloxy ethylene glycol (DSPE- mPEG), poly- oxyethylene sorbitan monopalmitate (Tween), polyethylene polypropylene glycol (poloxamer) and a mixture thereof may be used. Preferably, the polymer is contained in an amount of 10 to 30 parts by weight based on 100 parts by weight of the total lipid. When the content of the PEG containing polymer is below 10 parts by weight, the surface of the lipid nanosphere may not be sufficiently modified with PEG. In contrast, when the content of the PEG containing polymer exceeds 30 parts by weight, the surface of the lipid nanosphere is not further modified because the surface area is limited. With the introduction of PEG, an ion complex is formed by the anionic groups on the surface of the lipid nanosphere and the terminal amine groups of the PEG. Alternatively, PEG is introduced on the surface of the lipid nanosphere by the lipophilic binding between the liposoluble moieties of the PEG containing lipid, or other lipid, phospholipid and cholesterol.
[36] And, the "drug" means a poorly water soluble drug which is not easily encapsulable in conventional drug delivery systems. Amphotericin B is a typical example, but the present invention is not limited thereto.
[37] The present invention provides a "sustained release" lipid nanosphere which is stable in the blood, the surface of which being modified with anions or PEG. As used herein "surface modification" means a coating by mixing or ionic bonding of anions or PEG capable of extending circulation in the blood. And, as used herein, a "sustained release" lipid nanosphere refers to a formulation that remains in the bloodstream for at least 24 hours, whereas typical formulations disappear from the bloodstream within
several hours after administration.
[38] The lipid nanosphere of the present invention, in which amphotericin B is encapsulated and the surface of which is modified with anions, has an average particle size of 50 to 300 nm, preferably 100 to 150 nm. When the average particle size of the lipid nanosphere is larger than 300 nm, the lipid nanosphere may be uptaken by the reticuloendothelial system of such organs as liver or spleen during circulation in blood. In contrast, when the average particle size of the lipid nanosphere is smaller than 50 nm, the amount of the drug reaching the target site (drug payload) may not be sufficient.
[39] Hereunder, each step of the preparation method of the lipid nanosphere in which a drug is encapsulated and the surface of which is modified with anions is described in detail.
[40] First, the method (A) of mixing a PEG containing lipid with a lipid is as follows.
[41] In step (A-I), phosphatidylcholine, anionic phospholipid and sterolare mixed with a weight ratio of 40-70 : 5-20 : 10-40 to obtain a lipid. A lipid nanosphere is not formed easily when the content of phosphatidylcholine is less than the aforementioned range, and stability of the lipid nanosphere decreases when the content exceeds the aforementioned range. The size of the lipid nanosphere may increase and lipid nanospheres may coagulate with each other when the content of anionic phospholipid is less than the aforementioned range, and particle size may increase because of coagulation of lipid nanospheres with PEG when the content exceeds the aforementioned range. Further, encapsulation efficiency of the drug may decrease when the content of cholesterol is less than the aforementioned range, and stability of the lipid nanosphere may decrease when the content exceeds the aforementioned range. Encapsulation efficiency of the drug increases as the weight ratio of sterol increases. But, aforementioned range is preferred because particle size increases when the content of sterol exceeds the aforementioned range.
[42] One hundred parts by weight of thus prepared lipid is mixed with 10 to 30 parts by weight of a PEG containing polymer and dissolved in an organic solvent to obtain a lipid-PEG mixture solution.
[43] Coating of PEG may not be performed easily when the content of the PEG containing polymer is less than 10 parts by weight, and particle size becomes too large when the content the content exceeds 30 parts by weight. Hence, the aforementioned range is preferred to be kept. The lipid for forming the lipid nanosphere is dissolved in an organic solvent capable of dissolving lipids, such as chloroform, methanol, toluene, and the like.
[44] In step (A-2), a poorly water soluble drug is dissolved in a Ci-C6 linear or branched alcoholto obtain a drug solution. Examples of the Ci-C6 linear or branched alco-
holinclude methanol, ethanol, propanol, butanol, isobutanol, isopropanol, and the like. Preferably, the poorly water soluble drug is dissolved in the alcohol to a concentration of 0.1 to 1 mg/mL. When the poorly water soluble drug, preferably amphotericin B, is contained less than 0.1 mg/mL, the concentration of the encapsulated drug decreases. In contrast, when the concentration exceeds 1 mg/mL, the drug may not be completely dissolved in the alcohol. And, in case the drug is dissolved in an organic solvent other than alcohol, e. g., dimethyl sulfoxide (DMSO), dimethylformamide (DMF), etc., removal of the solvent may be complicated and biocompatibility may decrease.
[45] In step (A-3), the lipid-PEG mixture solution of step (A-I) and the drug solution of step (A-2) are mixed with a volume ratio of 1:1 to 1:9 to obtain a lipid-PEG-drug mixture solution. When the amount of the solution of step (A-I) exceeds 50 (v/v)%, concentration of the drug decreases. In contrast, when the amount is below 10 (v/v)%, formulation may be difficult because the quantity of the phospholipid is too small.
[46] In step (A-4), the lipid-PEG-drug mixture solution of step (A-3) is dispersed in an aqueous medium with a volume ratio of 2:1 to 1:10, more preferably 1:1 to 1:3, to obtain lipid nanospheres. For the aqueous medium, distilled water, phosphate buffer, saline solution, sugar solution, e.g., sucrose solution, maltose solution, mannitol solution, and the like, or isotonic solution may be used. When the volume of the aqueous medium is less than the aforementionedrange, the dispersed lipid nanosphere particles may coagulate, thereby resulting in increase in particle size of the final lipid nanospheres. In contrast, when the volume of the aqueous medium exceeds the aforementioned range, a concentration process may be required. Preferably, the dispersion for forming the lipid nanospheres is performed by dispersing the lipid-PEG-drug mixture solution of step (A-3) in water by tip sonication at a rate of 1 to 5 mL/min using a syringe. Particle size may increase when the dispersion rate exceeds the aforementioned range, and it is difficult to attain smaller particle size even when the dispersion rate is lower than the aforementioned range. Hence, the aforementioned range is preferred to be kept.
[47] In step (A-5), the lipid nanosphere solution of step (A-4) is distilled at 20 to 5O0C under reduced pressure to remove the organic solvent, and filtered to obtain lipid nanospheres with uniform particle size and having PEG groups, in which the drug is encapsulated. When the temperature during the distillation under reduced pressure is below 2O0C, it takes longer to remove the organic solvent and it is difficult to completely remove the organic solvent. In contrast, when the temperature exceeds 5O0C, the lipid nanospheres may be damaged or the drug may be denatured. Hence, it is preferable to maintain the aforementioned temperature range. For perfect removal of the organic solvent, it is preferable to remove, along with the organic solvent, 0.5 to 5 times the volume of water during the distillation under reduced pressure. The purified
lipid nanosphere solution is subjected to an injection molding machine to obtain a solution of lipid nanospheres having a uniform particle size distributed between 0.1 and 0.5 μm. Preferably, the filter membrane used in the injection molding machine has a pore size of 0.1 to 0.5 μm, identical to the particle size of the lipid nanospheres. When the pore size is larger than 0.5 μm, the particle size of the lipid nanosphere becomes larger than 0.5 μm, thus resulting in blockage at capillaries or uptake by reticuloendothelial cells during intraveneous injection, and consequent abrupt decrease of circulation time in the blood. In contrast, when the pore size is smaller than 0.1 μm, most of the particles pass through semipermeable membranes, thereby resulting in abrupt decrease of availability.
[48] Additionally, dialysis, gel permeation chromatography, filtration at high pressure, and the like may be performed to remove free PEGs remaining without being used to modify the lipid nanospheres. More preferably, gel permeation chromatography is performed to remove them along with phospholipids, drug, etc., remaining without being included in the lipid nanosphere.
[49] As another preparation method of the anionic lipid nanosphere according to the present invention, the method (B) of forming an ion complex comprising lipid and PEG having terminal amine groups is as follows.
[50] In step (B-I), phosphatidylcholine, anionic phospholipid and sterol are mixed with a weight ratio of 40-70 : 5-20 : 10-40 to obtain a lipid mixture solution, as in step (A-I).
[51] In step (B -2), a poorly water soluble drug is dissolved in a Ci-C6 linear or branched alcohol to obtain a drug solution, as in step (A-2).
[52] In step (B-3), the lipid mixture solution of step (B-I) and the drug solution of step
(B-2) are mixed with a volume ratio of 1:1 to 1:9 to obtain a lipid-drug mixture solution, as in step (A-3).
[53] In step (B-4), the mixture solution of step (B-3) is dispersed in an aqueous medium with a volume ratio of 2: 1 to 1:10, more preferably 1 : 1 to 1 :3, to obtain lipid nanospheres, as in step (A-4).
[54] In step (B-5), the lipid nanosphere solution of step (B-4) is distilled at 20 to 5O0C under reduced pressure to remove the organic solvent, and filtered to obtain lipid nanospheres with uniform particle size, in which the drug is encapsulated, as in step (A-5).
[55] In step (B-6), the lipid of step (B-I) is mixed with a PEG having terminal amine groups with a weight ratio of 100:10 to 100:30 and, after adjusting pH to 1 to 4, heating is performed at 40 to 650C for 10 to 30 minutes, so that the lipid and the PEG form an ion complex on the surface of the anionic lipid nanospheres, to obtain lipid nanospheres on which PEG is coated. That is, the PEG is coated on the surface of the lipid nanospheres as an ion complex is formed by the bonding of the anionic groups
present on the surface of the lipid nanospheres with the terminal amine groups of the PEG.
[56] An acidic pH condition is selected to facilitate the formation of an ion complex.
When the reaction temperature is below 5O0C, the reaction requires a longer time. In contrast, when reaction temperature is above 650C, stability of the lipid nanospheres may be deteriorated. Specific examples of the PEG having terminal amine groups include aminopolyethylene glycol, diaminopolyethylene oxide, amino(polyethylene glycol) methyl ether, and other polyethylene glycol or polyethylene oxide having terminal amine groups.
[57] Additionally, dialysis, gel permeation chromatography, filtration at high pressure, and the like may be performed to remove free PEGs remaining without being used to modify the lipid nanospheres. More preferably, gel permeation chromatography is performed to remove them along with phospholipids, drug, etc., remaining without being included in the lipid nanosphere.
[58] Thus prepared anionic lipid nanospheres have improved encapsulation efficiency of a poorly water soluble drug in an aqueous medium and increase circulation time in blood because the surface of the lipid nanospheres is modified by introducing the PEG containing polymer thereon. Accordingly, they are expected to be useful in solubilizing various poorly water soluble drugs, including amphotericin B.
[59]
Mode for the Invention
[60] The present invention is explained further with the following examples buth they should not be construed as limiting the scope of the present invention.
[61]
[62] Preparation Example 1
[63] 60 mg of phosphatidylcholine (PC) selected from dilauroyl phosphatidylcholine
(DLPC), dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC) and distearoyl phosphatidylcholine (DSPC) and 20 mg of cholesterol (CHOL) were dissolved in 2 mL of chloroform to obtain a lipid mixture solution.
[64] Amphotericin B (AmB) was dissolved in methanol to a concentration of 0.5 mg/mL.
2 mL of the lipid mixture solution was mixed with 8 mL of the amphotericin B solution to obtain 10 mL of an AmB-lipid mixture solution.
[65] The AmB-lipid mixture solution, in the amount of 10 mL, was dispersed in 20 mL of distilled water by tip sonication at a rate of 2 mL/min using a syringe to form lipid nanospheres. The organic solventand distilled water, in the amount of 10 mL, respectively, were removed at 350C by distillation under reduced pressure until the volume of the solution decreased to 10 mL. Particle size distribution of the lipid
nanospheres was made uniform by passing them through a 0.2 μm semipermeable membrane using an extruder.
[66] The particle size of thus prepared lipid nanospheres was measured with an elec- trophoretic light scattering spectrophotometer (ELS-Z, Otsuka Electronics, Japan). The result is given in the following Table 1.
[67] Table 1 [Table 1] [Table ]
[68] Preparation Example 2: Preparation of lipid nanospheres comprising anionic phos- pholipids [69] Anionic lipid nanospheres were prepared in the same manner as in Preparation Example 1, except for adding anionic phospholipids dipalmitoyl glycerophosphate (DPPA) or disteroyl glycerophosphoglycerol (DSPG) in order to improve the encapsulation of Sample 3, which has a particle size smaller than 150 nm and Tg of 410C, to 90% or better.
[70] Changes of particle size, zeta potential and encapsulation efficiency of the lipid nanospheres depending on the contents of DPPA and DSPG were measured. The result is given in the following Table 2 and Table 3.
[71] Table 2
[Table 2] [Table ]
[72] Table 3 [Table 3] [Table ]
[73] Preparation Example 3: Preparation of PEG coated lipid nanospheres (A) [74] Anionic lipid nanospheres were prepared in the same manner as in Preparation Example 2, except for adding 0 to 80 parts by weight of a DSPE-mPEG2000 solution to 100 parts by weight of the lipid mixture solution (Sample 8). Change of particle size depending on the content of DSPE-mPEG2000 is given in the following Table 4.
[75] Table 4
[Table 4] [Table ]
[76] Preparation Example 4: Preparation of PEG coated lipid nanospheres (B) [77] Surface of anionic lipid nanospheres was coated with PEG by adding a solution of PEG having terminal amine groups (mPEG-NH22000) to the lipid mixture solution (Sample 8) with a weight ratio of 0 to 80. After adjusting pH to 2, heating was performed at 550C for 20 minutes to form an ion complex. Change of particle sizedepending on the content of mPEG-NH2is given in the following Table5.
[78] Table 5 [Table 5] [Table ]
Composition (weight ratio) Particle size Enc ap s ulat ion
DPPC CHOL DPPA InPEG-NH2 (run) efficiency (%)
Sample S 60 20 20 0 108.6 96.9
Sample 17 60 20 20 10 109.5 96.9
Sample 18 60 20 20 20 109.7 96.9
Sample 19 60 20 20 40 128.1 96.9
Sample 20 60 20 20 80 184.7 96.9
[79] Test Example 1 : Circulation time in blood [80] Sodium deoxycholate was added to Fungizone (Bristol Myers-Squibb), AmBisome liposome (NeXstar Pharmaceuticals), Sample 8, Sample 14 and Sample 18 to solubilize amphotericin B. Thus prepared injections were administered to SD rats
through the tail vein. Blood was taken from the rats at different times to measure the concentration of the drug encapsulated in the lipid nanospheres. Pharmacokinetic parameters and circulation time in the blood were calculated from the measurement result. Concentrationof drug in the lipid nanospheres was measured as follows. The blood sample was diluted with heparin solution and centrifuged. The supernatant was diluted with a solution of 0.5 μg/mL of l-amino-4-nitronaphthalene in methanol. Ab- sorbance was measured using a UV spectrometer at a wavelength of 408 nm.
[81] The result is shown in FIG. 1.
[82] As can be seen from FIG. 1, the PEG coated lipid nanospheres according to the present invention [Sample 14 (Preparation Example 3) and Sample 18 (Preparation Example 4)] exhibited much longer circulation time in blood than Fungizone, and longer circulation time in blood than AmBisomeuntil 3 hours after injection. This demonstrates that the injections including the PEG coated anionic lipid nanospheres according to the present invention (Sample 14 and Sample 18) provide improved circulation time in blood over existing amphotericin B formulations.
[83]
[84] Test Example 2: Toxicity test
[85] MTT test was carried out using human kidney 293 cells. 293 cells were cultured on a
96- well plate, with a concentration of 1 104 cells/mL, in a CO2 incubator of 370C for 24 hours. To each well plate, amphotericin B was added with concentrations of 6.25, 12.5, 25, 50 and 100 μg/mL, and, after adding each of Fungizone, Sample 8, Sample 14 and Sample 18, the cells were further cultured in the CO2 incubator for 12 hours. After adding MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reagent, the cells were further cultured in the CO2 incubator at 370C for 4 hours to form formazan crystals. After removing 200 μg/mL of solution was from each well plate, the formazan crystals were dissolved by adding 150 μg/mL dimethyl sulfoxide solution. Enzyme-linked immunosorbent assay (ELISA) was carried out and the result was measured at 590 nm.
[86] The toxicity test result is shown in FIG. 2.
[87] As can be seen from FIG. 2, the lipid nanospheres according to the present invention
(Sample 14 and Sample 18) exhibited higher cell viability than Fungizone. It is believed that the toxicity of amphotericin B was decreased by the use of biocompatible phospholipid, cholesterol and PEG. This demonstrates that cell toxicity can be decreased by encapsulating amphotericin B in lipid nanospheres using biocompatible substances. Industrial Applicability
[88] As described above, the present invention relates to an anionic lipid nanosphere
having negative surface charge prepared by introducing PEG containing polymers on the surface of particles formed of anionic phospholipids to provide negative charge on the surface, thereby increasing encapsulation efficiency of a poorly water soluble drug in an aqueous medium, reducing toxicity of highly toxic drug against normal cells by encapsulating, and increasing the duration of systemic circulation, and a method of its preparation. The present invention will be very useful for solubilization poorly water soluble drugs such as amphotericin B in an aqueous medium for injection, reduction toxicity thereof and increaseof circulation time in blood.
[89] The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims
[1] An anionic lipid nanosphere for encapsulating a poorly water soluble drug wherein a polyethylene glycol (PEG) containing polymer is coated on the surface of particlesformed of anionic phospholipid.
[2] The lipid nanosphere according to claim 1, wherein the anionic phospholipid is contained in an amount of 5 to 20 weight % based on the entire lipid composition of the lipid nanosphere.
[3] The lipid nanosphere according to claim 1, wherein the poorly water soluble drug is amphotericin B.
[4] The lipid nanosphere according to claim 1, wherein the anionic phospholipid is phosphatidic acid having a hydrophobic Ci4-Ci8 alkyl chain.
[5] The lipid nanosphere according to claim 1, wherein the anionic phospholipid is selected from dimyristyl glycerophosphate (DMPA), dipalmitoyl glycerophosphate (DPPA), dimyristyl glycerophosphate (DMPG), disteroyl glycerophosphate (DSPA), disteroyl glycerophosphoglycerol (DSPG), dipalmitoyl glycerophosphoglycerol (DPPG), dimyristyl glycerophosphoserine (DMPS), dipalmitoyl glycerophosphoserine (DPPS), disteroyl glycerophosphoserine (DSPS) and a mixture thereof.
[6] The lipid nanosphere according to claim 1, wherein the PEG containing polymer is selected from disteroyl glycerophosphoethanolamine methyloxyethylene glycol (DSPE-mPEG), polyoxyethylene sorbitan monopalmitate (T ween), polyethylene polypropylene glycol (poloxamer) and a mixture thereof
[7] A preparation method of an anionic lipid nanosphere for encapsulating a poorly water soluble drug, comprising the steps of:
1) mixing 100 parts by weight of a lipid, which is prepared by mixing phosphatidylcholine, anionic phospholipid and sterol with a weight ratio of 40-70 : 5-20 : 10-40, with 10 to 30 parts by weight of a PEG containing polymer, and dissolving in an organic solvent to obtain a lipid-PEG mixture solution
2) dissolving a poorly water soluble drug in a Ci-C6 linear or branched alcohol to obtain a drug solution
3) mixing the lipid-PEG mixture solution of step 1) with the drug solution of step 2) with a volume ratio of 1 : 1 to 1 :9 to obtain a lipid-PEG-drug mixture solution
4) dispersing the mixture solution of step 3) in an aqueous medium with a volume ratio of 2: 1 to 1 : 10 to form lipid nanospheres and
5) distilling the lipid nanosphere solution of step 4) at 20 to 50°Cunder reduced pressure, removing the organic solvent, and filtering to obtain anionic lipid nanospheres with uniform size in which the drug is encapsulated.
[8] A preparation method of an anionic lipid nanosphere for encapsulating a poorly water soluble drug, comprising the steps of:
1) dissolving a lipid prepared by mixing phosphatidylcholine, anionic phospholipid and sterol with a weight ratio of 40-70 : 5-20 : 10-40 in an organic solvent to obtain a lipid mixture solution
2) dissolving a poorly water soluble drug in a Ci-C6 linear or branched alcohol to obtain a drug solution
3) mixing the lipid mixture solution of step 1) with the drug solution of step 2) with a volume ratio of 1 : 1 to 1 :9 to obtain a lipid-drug mixture solution
4) dispersing the mixture solution of step 3) in an aqueous medium with a volume ratio of 2: 1 to 1 : 10 to form lipid nanospheres
5) distilling the lipid nanosphere solution of step 4) at 20 to 5O0C under reduced pressure, removing the organic solvent, and filtering to obtain anionic lipid nanospheres with uniform size in which the drug is encapsulated and
6) mixing with a PEG having terminal amine groups with a weight ratio of the lipid of step 1) to the PEG having terminal amine groups being 100:10 to 100:30 to form lipid-PEG ion complexes.
[9] The preparation method of a lipid nanosphere according to claim 8 or 9, wherein the drug is amphotericin B. [10] The preparation method of a lipid nanosphere according to claim 8 or 9, wherein, in step 2), the drug is dissolved in the Ci-C6 linear or branched alcohol to a concentration of 0.1 to 1 mg/mL. [11] The preparation method of a lipid nanosphere according to claim 8 or 9, wherein, in step 4), the mixture solution of step 3) is dispersed by tip sonication at a rate of 1 to 5 mL/min using a syringe. [12] The preparation method of a lipid nanosphere according to claim 8 or 9, wherein, in step 5), along with the organic solvent, 0.5 to 5 times the volume of water is removed during the distillation under reduced pressure. [13] The preparation method of a lipid nanosphere according to claim 8 or 9, wherein, in step 5), the filtration is performed using a filter membrane having a pore size ofO.l to 0.5 μm in order to attain uniform particle size distribution. [14] The preparation method of a lipid nanosphere according to claim 9, wherein, in step 6), pH is adjusted to 1 to 4 to forman ion complex. [15] The preparation method of a lipid nanosphere according to claim 9, wherein, in step 6), reaction temperature is maintained at 40 to 650C to form an ion complex.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2007-0038959 | 2007-04-20 | ||
KR1020070038959A KR20080094473A (en) | 2007-04-20 | 2007-04-20 | Anionic lipid nanosphere and preparation method of the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008130137A1 true WO2008130137A1 (en) | 2008-10-30 |
Family
ID=39875628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/002174 WO2008130137A1 (en) | 2007-04-20 | 2008-04-17 | Anionic lipid nanosphere and preparation method of the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20080094473A (en) |
WO (1) | WO2008130137A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012091518A2 (en) * | 2010-12-31 | 2012-07-05 | 삼성전자주식회사 | Phospholipid nanoparticles for mr-induced high-intensity focused ultrasonic treatment and diagnosis, and method for producing same |
EP2398503A4 (en) * | 2009-02-13 | 2015-05-06 | Univ Washington | Gadolinium expressed lipid nanoparticles for magnetic resonance imaging |
WO2020055929A1 (en) * | 2018-09-11 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
US11633502B2 (en) | 2016-03-07 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
WO2023168418A1 (en) * | 2022-03-03 | 2023-09-07 | Massachusetts Institute Of Technology | Cell-wall binding protein specifically targeting cutibacterium acnes |
WO2023250209A3 (en) * | 2022-06-24 | 2024-02-01 | The Board Of Trustees Of The University Of Illinois | Formulation of an amphotericin b hybrid amide derivative in dsgpeg2k micelles |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102198900B1 (en) * | 2019-05-10 | 2021-01-07 | 서강대학교 산학협력단 | Nanoparticle complex for treating disease and Method for manufacturing the same |
KR102296341B1 (en) * | 2019-09-26 | 2021-08-30 | 한국화학연구원 | liposome nanosphere containing lipophilic antiaging ingredints and preparation method of the same |
KR20230120590A (en) | 2022-02-07 | 2023-08-17 | 한국과학기술원 | Oligonucleotides for gene delivery and lipid nanoparticles for gene delivery comprising the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214375B1 (en) * | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
WO2001034139A1 (en) * | 1999-11-11 | 2001-05-17 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
US20040126886A1 (en) * | 2000-09-25 | 2004-07-01 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
CA2596058A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Method of producing coated fine particles |
WO2007035783A2 (en) * | 2005-09-19 | 2007-03-29 | Celator Pharmaceuticals, Inc. | Combination formulations of cytidine analogs and platinum agents |
WO2007099377A2 (en) * | 2006-03-03 | 2007-09-07 | Parthenios Boulikas | Cancer treatments |
-
2007
- 2007-04-20 KR KR1020070038959A patent/KR20080094473A/en not_active Application Discontinuation
-
2008
- 2008-04-17 WO PCT/KR2008/002174 patent/WO2008130137A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214375B1 (en) * | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
WO2001034139A1 (en) * | 1999-11-11 | 2001-05-17 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
US20040126886A1 (en) * | 2000-09-25 | 2004-07-01 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
CA2596058A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Method of producing coated fine particles |
WO2007035783A2 (en) * | 2005-09-19 | 2007-03-29 | Celator Pharmaceuticals, Inc. | Combination formulations of cytidine analogs and platinum agents |
WO2007099377A2 (en) * | 2006-03-03 | 2007-09-07 | Parthenios Boulikas | Cancer treatments |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2398503A4 (en) * | 2009-02-13 | 2015-05-06 | Univ Washington | Gadolinium expressed lipid nanoparticles for magnetic resonance imaging |
US11207430B2 (en) | 2009-02-13 | 2021-12-28 | University Of Washington | Gadolinium expressed lipid nanoparticles for magnetic resonance imaging |
WO2012091518A2 (en) * | 2010-12-31 | 2012-07-05 | 삼성전자주식회사 | Phospholipid nanoparticles for mr-induced high-intensity focused ultrasonic treatment and diagnosis, and method for producing same |
WO2012091518A3 (en) * | 2010-12-31 | 2012-08-23 | 삼성전자주식회사 | Phospholipid nanoparticles for mr-induced high-intensity focused ultrasonic treatment and diagnosis, and method for producing same |
US11633502B2 (en) | 2016-03-07 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
WO2020055929A1 (en) * | 2018-09-11 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
WO2023168418A1 (en) * | 2022-03-03 | 2023-09-07 | Massachusetts Institute Of Technology | Cell-wall binding protein specifically targeting cutibacterium acnes |
WO2023250209A3 (en) * | 2022-06-24 | 2024-02-01 | The Board Of Trustees Of The University Of Illinois | Formulation of an amphotericin b hybrid amide derivative in dsgpeg2k micelles |
Also Published As
Publication number | Publication date |
---|---|
KR20080094473A (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008130137A1 (en) | Anionic lipid nanosphere and preparation method of the same | |
JP4885715B2 (en) | Irinotecan formulation | |
CA1339008C (en) | Amphotericin b liposome preparation | |
RU2577683C2 (en) | Liposomal composition and method of obtaining thereof | |
EP3603620A1 (en) | Liposome composition and pharmaceutical composition | |
CN102188377B (en) | Method for preparing medicine encapsulating liposome | |
Shaikh et al. | Aceclofenac organogels: in vitro and in vivo characterization | |
EP3138557B1 (en) | Liposome composition and method for producing same | |
CA2631243A1 (en) | Liposomal compositions | |
WO2009062299A1 (en) | Gel-stabilized liposome compositions, methods for their preparation and uses thereof | |
US20020058060A1 (en) | Liposome for incorporating large amounts of hydrophobic substances | |
EP3138555A1 (en) | Liposome composition and production method therefor | |
CN114652683A (en) | Mdivi-1 nano long-circulating liposome and preparation method and application thereof | |
EP3616726B1 (en) | Protein particle wrapped with medicine insoluble in water and preparation method therefor | |
JP2006273812A (en) | Method of manufacturing liposome preparation | |
CN111789816B (en) | Fluticasone furoate liposome suspension and preparation method thereof | |
CN102188379B (en) | Preparation method of drug-carrying liposome | |
CN102188378B (en) | Preparation method of liposome for coating and carrying water soluble drugs | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
WO2005021012A1 (en) | Drug carrier having gemcitabine enclosed therein | |
KR100832553B1 (en) | Heparin coated lipid nanosphere containing amphotericin b and preparation method of the same | |
JP4694776B2 (en) | Fine particle composition or liposome preparation | |
CN112168785B (en) | Ursolic acid liposome preparation, and preparation method and application thereof | |
RU2669374C2 (en) | Bis-naphthazarin based agent and method for production thereof | |
EP3395370B1 (en) | Liposome and liposome composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08741419 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08741419 Country of ref document: EP Kind code of ref document: A1 |